RAD51 and hepatocellular carcinoma: Thus, many RAD51 inhibitors, such as (E)-3-benzyl-2-(2-(pyridin-3-yl)vinyl)quinazolin-4(3H)-one (i.e., B02) and arsenic trioxide (ATO), have been validated as adjuvant therapies for HCC treatment and have been proven to enhance the effects of chemotherapy and radiotherapy [15,16,17].